1-methyl-5-(2-nitrophenyl)-1H-pyrazole | 305811-46-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-methyl-5-(2-nitrophenyl)-1H-pyrazole
• 英文别名: 1-methyl-5-(2-nitrophenyl)pyrazole
• CAS: 305811-46-5
• 化学式: C₁₀H₉N₃O₂
• 分子量: 203.2
• InChiKey: HHTRZPPRLKTUMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  63.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-methyl-5-(2-nitrophenyl)-1H-pyrazole 在 钯 氢气 作用下， 生成 2-(2-Methyl-2H-pyrazol-3-yl)-phenylamine
  参考文献：
  名称：

  2-(Anilinomethyl)imidazolines as α1 adrenergic receptor agonists: α1a subtype selective 2′-heteroaryl compounds

  摘要：

  The structure-activity relationship of 2'-pyrrole, pyrazole and triazole substituted 2-(anilinomethyl)imidazolines as alpha(1) adrenergic agonists was investigated. The size and orientation of substituents, as well as the position of the heteroatoms, were found to have a profound effect on the potency and selectivity of the molecules. Potent alpha(1A) subtype selective agonists have been identified. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00050-7
• 作为产物：
  描述：

  邻硝基苯乙酮 在 溶剂黄146 作用下， 生成 1-methyl-5-(2-nitrophenyl)-1H-pyrazole
  参考文献：
  名称：

  2-(Anilinomethyl)imidazolines as α1 adrenergic receptor agonists: α1a subtype selective 2′-heteroaryl compounds

  摘要：

  The structure-activity relationship of 2'-pyrrole, pyrazole and triazole substituted 2-(anilinomethyl)imidazolines as alpha(1) adrenergic agonists was investigated. The size and orientation of substituents, as well as the position of the heteroatoms, were found to have a profound effect on the potency and selectivity of the molecules. Potent alpha(1A) subtype selective agonists have been identified. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00050-7

文献信息

• Imidazoline derivatives as alpha-1A adrenoceptor ligands
  申请人：Bigham Eric Cleveland

  公开号：US06884801B1

  公开（公告）日：2005-04-26

  Compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed. Such compounds are useful in the treatment of Alpha-1A mediated diseases or conditions such as urinary incontinence.

  化合物的化学式（I）或其药用可接受的盐或溶剂的复合物已被披露。这些化合物在治疗Alpha-1A介导的疾病或症状，如尿失禁方面是有用的。
• Pyrazole compounds
  申请人：Hu Youhong

  公开号：US20060183751A1

  公开（公告）日：2006-08-17

  Aryl substituted pyrazole derivatives are provided, as well as processes for their preparation. The invention also provides compositions and methods for the treatment of HCV by administering a compound of the present invention, alone or in combination with additional antiviral agents, in a therapeutically effective amount.

  提供了取代芳基吡唑衍生物，以及它们的制备方法。该发明还提供了通过单独或与额外抗病毒药物联合使用本发明化合物的组合物和治疗HCV的方法，以治疗有效量。
• [EN] IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS<br/>[FR] DERIVES D'IMIDAZOLINE UTILISES COMME LIGANDS DU RECEPTEUR ADRENERGIQUE ALPHA-1A
  申请人：GLAXO GROUP LTD

  公开号：WO2000066563A1

  公开（公告）日：2000-11-09

  Compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed. Formula (i) wherein R?2, R3, R4 and R5¿ are independently H, halogen, -OH, -C¿1-3?alkyl, -C1-3alkoxy, -SC1-2alkyl, or -CF3, with the proviso that at least 2 of R?2, R3, R4 and R5¿ are H; R6 is H or -CH¿3; R?1 is -S(O)¿nR?7 where n is 1 or 2, -S(O)¿2NHR?8, -C(O)R?9, -NR14R15, -C(R17)=NOR16¿, (a) or a 5,6, or 7 membered heteroalkyl or heteroaryl group optionally substituted. Such compounds are useful in the treatment of Alpha-1A mediated diseases or conditions such as urinary incontinence.

  公开了式(I)的化合物或其药学上可接受的盐或溶剂化物。式(I)中，R?2、R3、R4和R5¿独立地为H、卤素、-OH、-C¿1-3?烷基、-C1-3烷氧基、-SC1-2烷基或-CF3，但至少有2个R?2、R3、R4和R5¿为H；R6为H或-CH¿3；R?1为-S(O)¿nR?7，其中n为1或2，-S(O)¿2NHR?8，-C(O)R?9，-NR14R15，-C(R17)=NOR16¿，(a)或可选择取代的5、6或7成员杂烷基或杂芳基基团。这些化合物在治疗α-1A介导的疾病或病况，例如尿失禁方面有用。
• IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1175406A1

  公开（公告）日：2002-01-30
• Pyrazole Compounds
  申请人：Hu Youhong

  公开号：US20130177529A1

  公开（公告）日：2013-07-11

  Aryl substituted pyrazole derivatives are provided, as well as processes for their preparation. The invention also provides compositions and methods for the treatment of HCV by administering a compound of the present invention, alone or in combination with additional antiviral agents, in a therapeutically effective amount.